Wells Fargo downgraded Viridian Therapeutics (VRDN) to Equal Weight from Overweight with a price target of $27, down from $37. The firm says its thesis on veligrotug played out in thyroid eye disease, and that the drug will get approved and be successful commercially. That said, the approval won’t be until the second half of 2026 along with VRDN-003’s Phase 3 data, Viridian’s key value driver, the analyst tells investors in a research note. It cites a lack of catalysts for the downgrade.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Top 3 Trending Stocks, According to Analysts – 12/18/2024
- Viridian Therapeutics price target raised to $47 from $44 at RBC Capital
- Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz
- Morning Movers: Viridian and Edgewise jump following successful trials
- Viridian Therapeutics Achieves Milestone in Phase 3 Trial